Truist Securities Reiterates Buy on Eli Lilly and Co, Maintains $850 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reiterated a Buy rating on Eli Lilly and Co (LLY) with a maintained price target of $850.
March 22, 2024 | 6:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities reaffirms a Buy rating on Eli Lilly with a price target of $850, indicating a positive outlook on the stock.
The reiteration of a Buy rating by a prominent analyst like Robyn Karnauskas, along with a high price target of $850, suggests a strong confidence in Eli Lilly's future performance. This endorsement is likely to instill positive sentiment among investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100